Rossari Biotech Yönetim

Yönetim kriter kontrolleri 4/4

Rossari Biotech CEO'su Sunil Chari, Jan2003 tarihinde atandı, in görev süresi 21.83 yıldır. in toplam yıllık tazminatı ₹ 12.13M olup, şirket hissesi ve opsiyonları dahil olmak üzere 100% maaş ve 0% ikramiyelerden oluşmaktadır. şirketin hisselerinin 30.87% ine doğrudan sahiptir ve bu hisseler ₹ 14.22B değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5 yıl ve 3.3 yıldır.

Anahtar bilgiler

Sunil Chari

İcra Kurulu Başkanı

₹12.1m

Toplam tazminat

CEO maaş yüzdesi	100.0%
CEO görev süresi	21.8yrs
CEO sahipliği	30.9%
Yönetim ortalama görev süresi	5yrs
Yönetim Kurulu ortalama görev süresi	3.3yrs

Son yönetim güncellemeleri

Why We Think Rossari Biotech Limited's (NSE:ROSSARI) CEO Compensation Is Not Excessive At All

Aug 17

Recent updates

Why We Think Rossari Biotech Limited's (NSE:ROSSARI) CEO Compensation Is Not Excessive At All

Aug 17

Is Rossari Biotech (NSE:ROSSARI) Using Too Much Debt?

Jun 14

Rossari Biotech's (NSE:ROSSARI) Solid Profits Have Weak Fundamentals

May 07

Analyst Estimates: Here's What Brokers Think Of Rossari Biotech Limited (NSE:ROSSARI) After Its Annual Report

May 03

One Analyst Just Shaved Their Rossari Biotech Limited (NSE:ROSSARI) Forecasts Dramatically

Feb 10

Returns On Capital At Rossari Biotech (NSE:ROSSARI) Paint A Concerning Picture

Sep 23

Returns On Capital Signal Tricky Times Ahead For Rossari Biotech (NSE:ROSSARI)

Apr 06

Need To Know: Analysts Are Much More Bullish On Rossari Biotech Limited (NSE:ROSSARI) Revenues

Feb 19

Rossari Biotech Limited Just Beat Revenue Estimates By 6.8%

Feb 17

I Ran A Stock Scan For Earnings Growth And Rossari Biotech (NSE:ROSSARI) Passed With Ease

Feb 10

Capital Allocation Trends At Rossari Biotech (NSE:ROSSARI) Aren't Ideal

Nov 24

With EPS Growth And More, Rossari Biotech (NSE:ROSSARI) Is Interesting

Oct 12

Is Rossari Biotech Limited's (NSE:ROSSARI) Latest Stock Performance Being Led By Its Strong Fundamentals?

Dec 17

Rossari Biotech (NSE:ROSSARI) Is Growing Earnings But Are They A Good Guide?

Oct 26

CEO Tazminat Analizi

Sunil Chari'un ücretlendirmesi Rossari Biotech'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	₹1b
Jun 30 2024	n/a	n/a	₹1b
Mar 31 2024	₹12m	₹12m	₹1b
Dec 31 2023	n/a	n/a	₹1b
Sep 30 2023	n/a	n/a	₹1b
Jun 30 2023	n/a	n/a	₹1b
Mar 31 2023	₹11m	₹11m	₹1b
Dec 31 2022	n/a	n/a	₹1b
Sep 30 2022	n/a	n/a	₹995m
Jun 30 2022	n/a	n/a	₹1b
Mar 31 2022	₹10m	₹10m	₹977m
Dec 31 2021	n/a	n/a	₹957m
Sep 30 2021	n/a	n/a	₹948m
Jun 30 2021	n/a	n/a	₹892m
Mar 31 2021	₹9m	₹9m	₹802m
Dec 31 2020	n/a	n/a	₹729m
Sep 30 2020	n/a	n/a	₹695m
Jun 30 2020	n/a	n/a	₹666m
Mar 31 2020	₹8m	₹7m	₹653m
Mar 31 2019	₹5m	n/a	₹457m
Mar 31 2018	₹9m	n/a	₹254m

Tazminat ve Piyasa: Sunil 'nin toplam tazminatı ($USD 143.58K ), Indian pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 260.56K ).

Tazminat ve Kazançlar: Sunil 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Sunil Chari (59 yo)

21.8yrs

Görev süresi

₹12,130,000

Tazminat

Mr. Sunil Srinivasan Chari serves as a Managing Director of Rossari Biotech Limited since September 26, 2019 and serves as its Director since 2009. He is a co-founder of Rossari Biotech Limited in 2003. He...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Edward Menezes	Co-Founder & Executive Chairman	15.8yrs	₹12.13m	31.13% ₹ 14.3b
Sunil Chari	Co-Founder	21.8yrs	₹12.13m	30.87% ₹ 14.2b
Ketan Sablok	Chief Financial Officer	1.5yrs	Veri yok	Veri yok
Mikhail Menezes	Director of Technical	no data	Veri yok	0.24% ₹ 110.8m
Parul Gupta	Company Secretary & Compliance Officer	5yrs	₹1.00m	Veri yok
Sunil Nair	Chief Human Resource Officer & Head Corporate Communications	less than a year	Veri yok	Veri yok
Yash Chari	Director of Marketing & Business Development	no data	Veri yok	0.30% ₹ 137.3m
Puneet Arora	Chief Executive Officer of Textile Chemicals Global	no data	Veri yok	Veri yok
Prasad Gadkari	President of Manufacturing	no data	Veri yok	Veri yok

5.0yrs

Ortalama Görev Süresi

49yo

Ortalama Yaş

Deneyimli Yönetim: ROSSARI 'un yönetim ekibi deneyimli ve deneyimlidir ( 5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Edward Menezes	Co-Founder & Executive Chairman	15.8yrs	₹12.13m	31.13% ₹ 14.3b
Sunil Chari	Co-Founder	15.8yrs	₹12.13m	30.87% ₹ 14.2b
Aseem Dhru	Independent Director	5yrs	₹2.87m	0.00018% ₹ 82.9k
Annoottam Ghosh	Member of Advisory Board	no data	Veri yok	Veri yok
Vikram Gupta	Member of Advisory Board	no data	Veri yok	Veri yok
Jean Marcopoulos	Member of Advisory Board	no data	Veri yok	Veri yok
Klaus Karl	Member of Advisory Board	no data	Veri yok	Veri yok
Aparna Sharma	Non-Executive Independent Director	1.5yrs	₹2.93m	Veri yok
Esha Achan	Additional Non-Executive Independent Director	1.1yrs	₹1.13m	Veri yok
Gurudas Aras	Non- Executive Independent Director	less than a year	Veri yok	Veri yok

3.3yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ROSSARI 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.3 yıldır).

Rossari Biotech Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Rossari Biotech Limited Appoints Gurudas Aras as an Additional Director Designated as Non- Executive Independent Director

Why We Think Rossari Biotech Limited's (NSE:ROSSARI) CEO Compensation Is Not Excessive At All

Rossari Biotech Limited, Annual General Meeting, Aug 23, 2024

Rossari Biotech Limited Announces Resignation of Melier Castelino as an Independent Director

Rossari Biotech Limited Appoints Ms. Aparna Sharma , as A Non-Executive, Independent Director, Effective 29Th April, 2023

Rossari Biotech Limited, Annual General Meeting, May 31, 2023

Recent updates

Now 22% undervalued after recent price drop

Rossari Biotech Limited Appoints Gurudas Aras as an Additional Director Designated as Non- Executive Independent Director

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

Rossari Biotech Limited to Report Q2, 2025 Results on Oct 19, 2024

Price target increased by 7.6% to ₹951

Rossari Biotech Limited Approves Dividend for the Financial Year Ended 31 March, 2024

Why We Think Rossari Biotech Limited's (NSE:ROSSARI) CEO Compensation Is Not Excessive At All

Upcoming dividend of ₹0.50 per share

Rossari Biotech Limited, Annual General Meeting, Aug 23, 2024

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Rossari Biotech Limited to Report Q1, 2025 Results on Jul 20, 2024

Is Rossari Biotech (NSE:ROSSARI) Using Too Much Debt?

Rossari Biotech's (NSE:ROSSARI) Solid Profits Have Weak Fundamentals

Analyst Estimates: Here's What Brokers Think Of Rossari Biotech Limited (NSE:ROSSARI) After Its Annual Report

Full year 2024 earnings: EPS misses analyst expectations

Rossari Biotech Limited to Report Q4, 2024 Results on Apr 29, 2024

Now 20% undervalued

Price target increased by 9.0% to ₹852

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 17%

Price target decreased by 8.4% to ₹782

Second quarter 2024 earnings released: EPS: ₹5.97 (vs ₹4.34 in 2Q 2023)

Rossari Biotech Limited to Report Q2, 2024 Results on Oct 21, 2023

First quarter 2024 earnings released: EPS: ₹5.30 (vs ₹5.21 in 1Q 2023)

Rossari Biotech Limited to Report Q1, 2024 Results on Jul 29, 2023

Rossari Biotech Limited Announces Resignation of Melier Castelino as an Independent Director

Investor sentiment improves as stock rises 16%

Rossari Biotech Limited Appoints Ms. Aparna Sharma , as A Non-Executive, Independent Director, Effective 29Th April, 2023

Upcoming dividend of ₹0.50 per share at 0.1% yield

Rossari Biotech Limited, Annual General Meeting, May 31, 2023

Rossari Biotech Limited, Annual General Meeting, May 31, 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment improves as stock rises 23%

Consensus revenue estimates fall by 13%

One Analyst Just Shaved Their Rossari Biotech Limited (NSE:ROSSARI) Forecasts Dramatically

Price target decreased by 9.2% to ₹986

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Rossari Biotech Limited Announces Resignation of Robin Banerjee as Non-Executive Independent Director

Insufficient new directors

Second quarter 2023 earnings released: EPS: ₹4.34 (vs ₹4.77 in 2Q 2022)

Rossari Biotech Limited to Report Q2, 2023 Results on Nov 05, 2022

Returns On Capital At Rossari Biotech (NSE:ROSSARI) Paint A Concerning Picture

First quarter 2023 earnings released: EPS: ₹5.21 (vs ₹4.52 in 1Q 2022)

Rossari Biotech Limited to Report Q1, 2023 Results on Aug 06, 2022

Rossari Biotech Limited Approves Dividend for the Financial Year Ended March 31, 2022, Payable on or After July 21, 2022

Upcoming dividend of ₹0.50 per share

Full year 2022 earnings: EPS misses analyst expectations

Rossari Biotech Limited Recommended Final Dividend for the Financial Year Ended March 31, 2022, Payable on or After July 21, 2022

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Rossari Biotech Limited Proposes Final Dividend for the Financial Year Ended March 31, 2022

Rossari Biotech Limited, Annual General Meeting, Jul 15, 2022

Price target decreased to ₹1,252

Returns On Capital Signal Tricky Times Ahead For Rossari Biotech (NSE:ROSSARI)

Need To Know: Analysts Are Much More Bullish On Rossari Biotech Limited (NSE:ROSSARI) Revenues

Rossari Biotech Limited Just Beat Revenue Estimates By 6.8%

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Price target decreased to ₹1,330

I Ran A Stock Scan For Earnings Growth And Rossari Biotech (NSE:ROSSARI) Passed With Ease

Capital Allocation Trends At Rossari Biotech (NSE:ROSSARI) Aren't Ideal

Second quarter 2022 earnings released: EPS ₹4.77 (vs ₹4.07 in 2Q 2021)

With EPS Growth And More, Rossari Biotech (NSE:ROSSARI) Is Interesting

Insider recently sold ₹2.1m worth of stock

Price target increased to ₹1,270

First quarter 2022 earnings released: EPS ₹4.52 (vs ₹3.19 in 1Q 2021)

Rossari Biotech Reportedly in Advanced Talks to Acquire Specialty Chemicals Business

Rossari Biotech Limited (BSE:543213) entered in an agreement to acquire Unitop Chemicals Pvt. Ltd. for approximately INR 4.2 billion.

Full year 2021 earnings released: EPS ₹15.56 (vs ₹13.42 in FY 2020)

Investor sentiment improved over the past week

Rossari Biotech Limited announced that it expects to receive INR 2.999997816 billion in funding from Malabar Investments, LLC, State Bank of India, Asset Management Arm and other investors